Eli Lilly and Company (LLY)vsOwlet Inc (OWLT)
LLY
Eli Lilly and Company
$1,131.42
+0.32%
HEALTHCARE · Cap: $1.01T
OWLT
Owlet Inc
$5.11
+3.23%
HEALTHCARE · Cap: $145.01M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 67385% more annual revenue ($72.25B vs $107.06M). LLY leads profitability with a 35.0% profit margin vs -43.0%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
OWLT
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -526.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : OWLT
OWLT has a balanced fundamental profile.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : OWLT
The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while OWLT is a turnaround play — different risk/reward profiles.
OWLT carries more volatility with a beta of 1.86 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 28/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Owlet Inc
HEALTHCARE · MEDICAL DEVICES · USA
Owlet Inc. is a pioneering leader in infant health technology, focused on enhancing the safety and wellness of newborns through its innovative monitoring solutions. Its flagship product, the Owlet Smart Sock, utilizes advanced pulse oximetry to deliver real-time insights into heart rates and oxygen levels, allowing parents to access crucial health data via mobile devices. As demand for pediatric health monitoring continues to rise, Owlet is strategically positioned to expand its product portfolio and strengthen its market presence. The company's commitment to delivering actionable health information and improving pediatric care aligns closely with institutional investors' interests in the rapidly evolving landscape of health technology.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?